In response to elevated SREBP1c, the expression of downstream targets ACC and FASN was increased in both patients and animal models with NAFLD [18, 44, 45, 53–57]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.